The Conversation (0)
March 24, 2025
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
29 August 2025
FY25 Preliminary Results Summary and Company Update
Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
29 August 2025
Appendix 4E
Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Appendix 4C
Cardiex Limited (CDX:AU) has announced June Quarterly Appendix 4CDownload the PDF here. Keep Reading...
31 July 2025
June Quarterly Activities Report
Cardiex Limited (CDX:AU) has announced June Quarterly Activities ReportDownload the PDF here. Keep Reading...
24 June 2025
Results of Entitlement Offer
Cardiex Limited (CDX:AU) has announced Results of Entitlement OfferDownload the PDF here. Keep Reading...
21h
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
23 June
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Potentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following... Keep Reading...
17 June
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms,... Keep Reading...
17 June
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
(TheNewswire) More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs Kelowna, British Columbia TheNewswire - June 17, 2026 Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug... Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00